Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients

June 6, 2017

This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.

In this video, Rachel A. Freedman, MD, MPH, of the Dana-Farber Cancer Institute, discusses results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.

Freedman presented the results of the study (abstract 1005) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.